Thrombocytopenia Treatment Market Size, Share, and COVID-19 Impact Analysis By Drug Class (Corticosteroids, Platelet Stimulating Agents, and Lysosomal Enzyme), By Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, and Online Pharmacies), and Regional Forecast, 2025-2032

Thrombocytopenia is characterized by abnormally low levels of platelets in the blood. The cause of this condition is low platelet production, accelerative platelet destruction induced by medication, or other associated clinical conditions such as pregnancy, and liver cirrhosis. Medications, blood or platelet transfusions, and surgery, are the line of treatments for low platelet count. Persistent or severe thrombocytopenia can cause serious bleeding and secondary conditions in patients. The incidence of thrombocytopenia among the global population is rising owing to changes in sedentary lifestyles and several nutritional deficiencies. According to data from Swedish Orphan Biovitrum AB (SOBI), the incidence of new cases of thrombocytopenia is around 3.3 for every 100,000 people each year across the globe.

The global rise in clinical diagnosis & screening for thrombocytopenia and new treatment opportunities for clinical manifestation will boost the market growth. Also, the increasing demand for thrombocytopenia therapies in secondary conditions such as pregnancy will further augment market growth. For instance, as per Medscape estimates, in March 2021, thrombocytopenia, or a low blood platelet count, is encountered in 7-12% of all pregnancies globally, of which 30.0% of women require treatment. However, adverse effects associated with available therapies such as corticosteroids may hamper the market growth.

Impact of COVID-19 on the Thrombocytopenia Treatment Market

The COVID-19 outbreak had a measurable impact on the rapid growth of the thrombocytopenia treatment market. The travel restrictions and temporary lockdowns imposed by the government had led to a decline in the number of surgical procedures, elective medical procedures, and patients seeking treatment at hospitals. This led to severe shortages of critical medical supplies and low availability of treatment beds across healthcare centers owing to the rapid rise of COVID-19 cases across the globe. Moreover, pharmaceutical companies, and significant research institutes of the drugs, limited the manufacturing of thrombocytopenia medicines due to the shortage of raw materials and transportation.

However, post-COVID-19 pandemic, the market encountered a positive impact from the increasing need to develop advanced diagnostic and therapeutic options for patients suffering from thrombocytopenia and related disorders. Similarly, growing initiatives by key players for the production of new thrombocytopenia medications and regulatory agencies to provide faster approval to these candidates further augmented the market growth. For instance, as per published articles by Sanofi, in November 2020, the U.S. Food and Drug Administration (FDA) granted Fast Track Designation (FTD) to rilzabrutinib for the treatment of immune thrombocytopenia (ITP).

Key Insights

The report will cover the following key insights:

• Prevalence of Thrombocytopenia, by Key Countries, 2022.
• New Product Launches by Key Players, 2022.
• Key Industry Developments – Partnerships, Mergers and Acquisitions.
• Impact of COVID-19 on the Market.

Analysis by Drug Class:

Based on drug class, the market is segmented into corticosteroids, platelet-stimulating agents, and lysosomal enzymes. The corticosteroids are expected to grow at the highest CAGR owing to easy availability, cost-effectiveness, and greater efficiency than other medications. Moreover, rising demand for glucocorticoids among healthcare professionals due to their short treatment regimens and rapid line of action will further augment segment growth. Moreover, the rising introduction and presence of new products for thrombocytopenia treatment by key players across emerging nations will propel the segment market.

• As per a study published by the Journal of Blood Medicine on Dove Press Ltd, in July 2021, corticosteroids are the standard first-line treatment and most common rescue therapy in newly diagnosed thrombocytopenia patients. Corticosteroids have been shown to reduce platelet autoantibody production, increase platelet production, and decrease platelet destruction as compared to another standard line of treatments.

Regional Analysis:

To gain extensive insights into the market, Download for Customization

North America is anticipated to lead the global thrombocytopenia treatment market with a significant revenue share and is expected to flourish prominently during the analysis period. The region's significant growth is mainly attributed to the rising prevalence of thrombocytopenia among the population and rising investments in clinical research for developing new drugs by biotechnology and pharmaceutical companies across North America. Moreover, increasing awareness regarding thrombocytopenia among the North American population and the presence of large market players are also prominently anticipated to boost the adoption of the thrombocytopenia treatment market during the forecast period.

Key Players Covered:

The report will include key players such as Amgen Inc., Bayer AG, Novartis AG, Intas Pharmaceuticals Ltd., Rigel Pharmaceuticals, Inc., Shionogi & Co., Ltd., Boehringer Ingelheim GmbH, Dova Pharmaceuticals, Inc., and other prominent players.

Segmentation

Key Industry Developments

• March 2022: the pacritnib drug developed by biopharmaceutical company, CTI BioPharma, received FDA approval to treat severe thrombocytopenia.
• November 2021: Sobi, Inc., announced topline results from its phase 3 study of avatrombopag, an oral thrombopoietin (TPO) receptor agonist for the treatment of chemotherapy-induced thrombocytopenia in adults with active non-hematological cancers.
• May 2018: the US Food and Drug Administration (FDA) approved Dova Pharmaceuticals’ Doptelet drug for patients with thrombocytopenia.